Cargando…

ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

Multidrug resistance (MDR) is one of the most important contributors to the high mortality of cancer and remains a major concern. We previously found that zinc finger protein 32 (ZNF32), an important transcription factor associated with cancer in Homo sapiens, protects tumor cells against cell death...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Ao, Jie, Li, Kai, Zhang, Jie, Li, Yanyan, Zhang, Le, Wei, Yuyan, Gong, Di, Gao, Junping, Tan, Weiwei, Huang, Lugang, Liu, Lunxu, Lin, Ping, Wei, Yuquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133992/
https://www.ncbi.nlm.nih.gov/pubmed/27763636
http://dx.doi.org/10.1038/cddis.2016.328
_version_ 1782471385049726976
author Li, Jun
Ao, Jie
Li, Kai
Zhang, Jie
Li, Yanyan
Zhang, Le
Wei, Yuyan
Gong, Di
Gao, Junping
Tan, Weiwei
Huang, Lugang
Liu, Lunxu
Lin, Ping
Wei, Yuquan
author_facet Li, Jun
Ao, Jie
Li, Kai
Zhang, Jie
Li, Yanyan
Zhang, Le
Wei, Yuyan
Gong, Di
Gao, Junping
Tan, Weiwei
Huang, Lugang
Liu, Lunxu
Lin, Ping
Wei, Yuquan
author_sort Li, Jun
collection PubMed
description Multidrug resistance (MDR) is one of the most important contributors to the high mortality of cancer and remains a major concern. We previously found that zinc finger protein 32 (ZNF32), an important transcription factor associated with cancer in Homo sapiens, protects tumor cells against cell death induced by oxidative stress and other stimuli. We thus hypothesized that ZNF32 might enable the tolerance of cancer cells to anti-tumor drugs because higher ZNF32 expression has been found in cancer tissues and in drug-resistant lung adenocarcinoma (AC) cells. In this study, we found that ZNF32 is upregulated by Sp1 (specificity protein 1) in response to drug treatment and that ZNF32 promotes drug resistance and protects AC cells against cisplatin or gefitinib treatment. ZNF32 overexpression in AC cells conferred resistance to EGFR (epidermal growth factor receptor) inhibitors by enhancing MEK/ERK activation. Moreover, ZNF32 was found to directly bind to the TGF-βR2 (transforming growth factor-beta receptor 2) promoter to promote its expression, and ZNF32-induced resistance was mediated by enhancing TGF-βR2 expression and activating the TGF-βR2/SMAD2 pathway. In both a mouse model and ex vivo cultured patient samples, a high level of ZNF32 expression was closely associated with worse overall survival and cisplatin resistance. ZNF32 appears to be a potential inducer of drug resistance that could increase the expression of the drug resistance-associated gene TGF-βR2 and subsequently facilitate the induction of drug resistance during both conventional chemotherapy and novel target therapy. Thus, ZNF32-associated target therapy is a potential novel adjuvant therapy that might effectively prevent the occurrence of multidrug resistance (MDR) during chemotherapy and improve the survival of patients with AC.
format Online
Article
Text
id pubmed-5133992
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51339922016-12-16 ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma Li, Jun Ao, Jie Li, Kai Zhang, Jie Li, Yanyan Zhang, Le Wei, Yuyan Gong, Di Gao, Junping Tan, Weiwei Huang, Lugang Liu, Lunxu Lin, Ping Wei, Yuquan Cell Death Dis Original Article Multidrug resistance (MDR) is one of the most important contributors to the high mortality of cancer and remains a major concern. We previously found that zinc finger protein 32 (ZNF32), an important transcription factor associated with cancer in Homo sapiens, protects tumor cells against cell death induced by oxidative stress and other stimuli. We thus hypothesized that ZNF32 might enable the tolerance of cancer cells to anti-tumor drugs because higher ZNF32 expression has been found in cancer tissues and in drug-resistant lung adenocarcinoma (AC) cells. In this study, we found that ZNF32 is upregulated by Sp1 (specificity protein 1) in response to drug treatment and that ZNF32 promotes drug resistance and protects AC cells against cisplatin or gefitinib treatment. ZNF32 overexpression in AC cells conferred resistance to EGFR (epidermal growth factor receptor) inhibitors by enhancing MEK/ERK activation. Moreover, ZNF32 was found to directly bind to the TGF-βR2 (transforming growth factor-beta receptor 2) promoter to promote its expression, and ZNF32-induced resistance was mediated by enhancing TGF-βR2 expression and activating the TGF-βR2/SMAD2 pathway. In both a mouse model and ex vivo cultured patient samples, a high level of ZNF32 expression was closely associated with worse overall survival and cisplatin resistance. ZNF32 appears to be a potential inducer of drug resistance that could increase the expression of the drug resistance-associated gene TGF-βR2 and subsequently facilitate the induction of drug resistance during both conventional chemotherapy and novel target therapy. Thus, ZNF32-associated target therapy is a potential novel adjuvant therapy that might effectively prevent the occurrence of multidrug resistance (MDR) during chemotherapy and improve the survival of patients with AC. Nature Publishing Group 2016-10 2016-10-20 /pmc/articles/PMC5133992/ /pubmed/27763636 http://dx.doi.org/10.1038/cddis.2016.328 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Li, Jun
Ao, Jie
Li, Kai
Zhang, Jie
Li, Yanyan
Zhang, Le
Wei, Yuyan
Gong, Di
Gao, Junping
Tan, Weiwei
Huang, Lugang
Liu, Lunxu
Lin, Ping
Wei, Yuquan
ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title_full ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title_fullStr ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title_full_unstemmed ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title_short ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
title_sort znf32 contributes to the induction of multidrug resistance by regulating tgf-β receptor 2 signaling in lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133992/
https://www.ncbi.nlm.nih.gov/pubmed/27763636
http://dx.doi.org/10.1038/cddis.2016.328
work_keys_str_mv AT lijun znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT aojie znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT likai znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT zhangjie znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT liyanyan znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT zhangle znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT weiyuyan znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT gongdi znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT gaojunping znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT tanweiwei znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT huanglugang znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT liulunxu znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT linping znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma
AT weiyuquan znf32contributestotheinductionofmultidrugresistancebyregulatingtgfbreceptor2signalinginlungadenocarcinoma